Maui,
Thanks for the response. I think the NAM simply means Negative Allosteric Modulator (NAM).

From my post.

Pipeline Update
Dipraglurant (mGluR5NAM):

Quote:

---

About Addex Therapeutics
Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2A POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter Phase 2B for PD-LID.

---

http://www.addextherapeutics.com/investors/pr...ic-update/


From your post.

Quote:

---

Abstract


The present invention relates in one embodiment to a pharmaceutical combination of a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator and levodopa or a dopamine agonist, and at least one of a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor for the treatment of PD-LID. In this exemplary pharmaceutical combination, the mGluR5 negative allosteric modulator will have similar pharmacokinetic parameters to levodopa or to a dopamine agonist.

---

http://www.google.com/patents/WO2013139941A1?cl=en

Just looking through it, it appears to be one in the same.

dipraglurant=metabolic glutamate receptor5=mGluR5=mGluR5NAM

That was a good find, I don't know about the patents but it sure is interesting that the CMO and co-inventors of dipraglurant would leave Addex to join AMBS.

GLTA,
Hoosier